Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "DNA damage process" refers broadly to the collection of events by which cells recognize and respond to various forms of injury inflicted upon their genetic material. This includes detection mechanisms that sense damaged bases or strand breaks; signaling cascades that halt cell division; recruitment and activation of specialized proteins responsible for excision, reversal, or bypassing lesions; and ultimate decisions between successful restoration versus programmed cell death if errors are irreparable. The main types include direct reversal mechanisms, base excision repair, nucleotide excision repair, mismatch correction systems, non-homologous end joining (NHEJ), homologous recombination (HR), among others[1][2][3]. While individual proteins within these pathways are valid therapeutic targets—especially in oncology—the overall "process" is not considered a discrete molecular entity suitable for targeted drug development.
Drugs targeting this area generally: - Inhibit specific enzymes required for DNA repair, leading to accumulation of lethal lesions. - Induce excessive DNA damage beyond the capacity for cellular repair, triggering apoptosis.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA damage process.